Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Tasly Pharmaceutical Group Co., Ltd
  6. Company
    600535   CNE000001C81

TASLY PHARMACEUTICAL GROUP CO., LTD

(600535)
  Report
End-of-day quote Shanghai Stock Exchange  -  2023-01-19
11.63 CNY   +0.95%
2022Tasly Pharmaceutical Gets Go Ahead to Launch Clinical Trial of Diabetic Kidney Drug
MT
2022Mauna Kea Technologies reports its Financial Results for the First Half of 2022
AQ
2022Mauna Kea Technologies and Tasly Pharmaceutical Announces the Incorporation of Joint Venture in China
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Tasly Pharmaceutical Group Co Ltd is a China-based company principally engaged in the manufacture and distribution of pharmaceutical products. The Company's main businesses include the manufacture and sales of traditional Chinese medicines, chemical preparations, chemical raw materials and biological medicines. The Company's main products include Compound Danshen Dropping Pills, Yangxuenao Granules, Yangxuenao Pills, Qishen Yiqi Dropping Pills, Diqing and Shuilinjia. Its products are used to treat cardiovascular and cerebrovascular diseases, tumors, colds, fevers and liver diseases. The Company mainly distributes its products in the domestic market.

Number of employees : 9 437 people.
Sales per Business
20202021Delta
Pharmaceutical Industry6 382.9247%6 654.0983.7% +4.25%
Pharmaceutical Commerce7 122.3852.5%1 244.0115.6% -82.53%
Other Business70.820.5%53.860.7% -23.95%
CNY in Million
Sales per region
20202021Delta
China13 576.10100%7 951.96100% -41.43%
CNY in Million
Managers
Name Title Age Since
Jing Su Director 59 2018
Jie Wei Chief Financial Officer 45 2018
Ying Zhao Securities Affairs Representative - -
Jie Yu Board Secretary 47 2017
Members of the board
Name Title Age Since
Kai Jing Yan Chairman 43 2014
Zheng Liang Ye, Dr. Chairman-Supervisory Board 55 2018
Ai Jian Wang, Dr. Independent Director 68 2021
Liu Xin Independent Director 54 2018
Bin Zhang Independent Director 68 2021
Xiao Meng Jiang Vice Chairman 58 2007
Nai Feng Wu, Dr. Director 70 2005
Jin Yong Cai Member-Supervisory Board 50 2006
He Sun Vice Chairman 63 2015
Yong Hong Zhu, Dr. Director 57 2013
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,499,700,130 760,253,749 50.7% 5,750,125 0.4% 50.7%
Shareholders
NameEquities%
Kai Jing Yan 725,160,596 48.4%
Shao Luan Liu 9,150,120 0.61%
Da Cheng Fund Management Co., Ltd. 8,592,406 0.57%
China Southern Asset Management Co., Ltd. 8,394,306 0.56%
GF Fund Management Co., Ltd. 8,345,845 0.56%
Yinhua Fund Management Co., Ltd. 8,045,680 0.54%
E Fund Management Co., Ltd. 7,751,244 0.52%
Zhong Ou Asset Management Co., Ltd 7,592,246 0.51%
Tianijn Shunqi Technology Development Partnership LP 7,252,158 0.48%
China Asset Management Co., Ltd. 7,007,371 0.47%
Company contact information
Tasly Pharmaceutical Group Co., Ltd.
No. 2, Puji River East Road
Beichen District
Tianjin 300410

Phone : +86.22.26736999
Fax : +86.22.26736721
Web : http://www.tasly.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Tasly Pharmaceutical Group Co., Ltd